Krystal Biotech (NASDAQ:KRYS) Stock Rating Upgraded by BidaskClub

Krystal Biotech (NASDAQ:KRYS) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Wednesday, BidAskClub reports.

Several other equities analysts also recently weighed in on KRYS. Guggenheim set a $81.00 target price on Krystal Biotech and gave the company a “buy” rating in a research report on Thursday, September 26th. William Blair restated a “buy” rating on shares of Krystal Biotech in a research report on Monday, November 4th. Cowen restated a “buy” rating on shares of Krystal Biotech in a research report on Tuesday. HC Wainwright set a $59.00 target price on Krystal Biotech and gave the company a “buy” rating in a research report on Wednesday, September 4th. Finally, Zacks Investment Research upgraded Krystal Biotech from a “sell” rating to a “hold” rating and set a $47.00 target price on the stock in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $59.33.

NASDAQ:KRYS traded up $0.67 during mid-day trading on Wednesday, hitting $42.56. 112,500 shares of the company’s stock traded hands, compared to its average volume of 143,971. The company has a market capitalization of $744.44 million, a P/E ratio of -43.88 and a beta of 1.03. The company has a fifty day moving average of $39.26 and a 200 day moving average of $39.28. Krystal Biotech has a twelve month low of $16.82 and a twelve month high of $51.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 49.80 and a current ratio of 54.87.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 4th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.14. On average, research analysts expect that Krystal Biotech will post -1.37 earnings per share for the current fiscal year.

In related news, Director Daniel Janney sold 88,684 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $46.46, for a total value of $4,120,258.64. Following the completion of the sale, the director now owns 35,131 shares of the company’s stock, valued at $1,632,186.26. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 34.30% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of the stock. Wells Fargo & Company MN increased its holdings in shares of Krystal Biotech by 3.1% in the second quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock valued at $381,000 after purchasing an additional 280 shares during the last quarter. Bank of Montreal Can acquired a new stake in shares of Krystal Biotech in the second quarter valued at approximately $29,000. Rhumbline Advisers increased its holdings in shares of Krystal Biotech by 18.6% in the third quarter. Rhumbline Advisers now owns 10,270 shares of the company’s stock valued at $357,000 after purchasing an additional 1,614 shares during the last quarter. Tower Research Capital LLC TRC acquired a new stake in shares of Krystal Biotech in the second quarter valued at approximately $72,000. Finally, California Public Employees Retirement System increased its holdings in shares of Krystal Biotech by 17.8% in the third quarter. California Public Employees Retirement System now owns 13,479 shares of the company’s stock valued at $468,000 after purchasing an additional 2,038 shares during the last quarter. 56.50% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.

Featured Article: Why do commodities matter?

Analyst Recommendations for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.